Related Experiment Video
Updated: May 18, 2026
18:46
Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs
Published on: December 9, 2010
Cytolytic nanoparticles attenuate HIV-1 infectivity
Joshua L Hood1, Andrew P Jallouk, Nancy Campbell
1Consortium for Translational Research in Advanced Imaging and Nanomedicine, Department of Medicine, Division of Cardiology, Washington University School of Medicine, St Louis, MO, USA. jhood@dom.wustl.edu
Antiviral Therapy
|September 8, 2012
Summary
Melittin-loaded nanoparticles effectively inhibit HIV-1 infectivity without harming vaginal cells, offering a promising new topical virucide. These nanoparticles safely reduce viral load and capture the virus, demonstrating potential for HIV prevention.
Area of Science:
- Nanotechnology
- Virology
- Drug Delivery
Background:
- Investigated melittin peptides encapsulated in nanoparticles as a potential topical vaginal virucide against HIV-1.
- Compared free melittin and nanoparticle-delivered melittin for cytotoxicity and anti-HIV-1 activity.
Purpose of the Study:
- To evaluate the safety and efficacy of melittin-loaded nanoparticles in inhibiting HIV-1 infectivity.
- To assess the potential of nanoparticle constructs as a vaginal virucide.
Main Methods:
- Prepared and characterized free melittin and melittin-loaded nanoparticles.
- Assessed cytotoxicity against TZM-bl reporter cells and VK2 vaginal epithelial cells.
- Determined the inhibitory concentration (IC50 and IC90) against CXCR4 and CCR5 tropic HIV-1 strains.
- Evaluated nanoparticle capture of HIV-1 via low-speed centrifugation.
Main Results:
- Free melittin showed high anti-HIV-1 activity but was cytotoxic to vaginal cells.
- Melittin nanoparticles were non-cytotoxic to vaginal cells at all tested doses.
- Melittin nanoparticles significantly inhibited both CXCR4 and CCR5 tropic HIV-1 strains.
- Nanoparticles demonstrated enhanced capture of HIV-1 compared to blank nanoparticles.
Conclusions:
- Melittin-loaded nanoparticles represent a safe and effective strategy for inhibiting HIV-1 infectivity.
- This study provides proof-of-concept for nanoparticle-mediated antiviral therapy.
- Further research is warranted to explore the prophylactic potential of melittin nanoparticles against HIV-1 and other enveloped viruses.
